A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‑kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies.
I. W. Flinn
Research Funding - Calistoga Pharmaceuticals
M. T. Schreeder
No relevant relationships to disclose
S. E. Coutre
No relevant relationships to disclose
J. Leonard
No relevant relationships to disclose
N. D. Wagner-Johnston
No relevant relationships to disclose
S. De Vos
No relevant relationships to disclose
R. V. Boccia
No relevant relationships to disclose
L. Holes
Employment or Leadership Position - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals
S. Peterman
Employment or Leadership Position - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals
L. L. Miller
Employment or Leadership Position - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals
A. S. Yu
Employment or Leadership Position - Calistoga Pharmaceuticals
Stock Ownership - Calistoga Pharmaceuticals